Diana Elizabeth Tullis


Associate Scientist, Li Ka Shing Knowledge Institute


As the Director of the Toronto Adult Cystic Fibrosis (CF) Clinic at St. Michael’s Hospital, Dr. Tullis is responsible for the care of 450 adults with CF. Dr. Tullis is a Professor of Medicine at the University of Toronto, the Respirology Division Head at St. Michael’s Hospital, and an Adjunct Scientist at the Keenan Research Centre of Li Ka Shing Knowledge Institute. She is the Cystic Fibrosis Canada Chair in Adult CF Research.

Dr. Tullis has published over 100 articles and book chapters and has lectured nationally and internationally on issues related to CF in adults. She has had 25 years of experience with CF clinical care. She was the Chair of the Clinic Subcommittee of the Medical/Scientific Advisory Board of Cystic Fibrosis Canada from 2005-2011 and in 2010 was a Coach for the Adult Quality Improvement Program run by the American Cystic Fibrosis Foundation.

Recent Publications

  1. Strug, LJ, Gonska, T, He, G, Keenan, K, Ip, W, Boëlle, PY et al.. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. Hum. Mol. Genet. 2016; :. doi: 10.1093/hmg/ddw290. PubMed PMID:27571897 .
  2. Kim, SH, Clark, ST, Surendra, A, Copeland, JK, Wang, PW, Ammar, R et al.. Global Analysis of the Fungal Microbiome in Cystic Fibrosis Patients Reveals Loss of Function of the Transcriptional Repressor Nrg1 as a Mechanism of Pathogen Adaptation. PLoS Pathog. 2015;11 (11):e1005308. doi: 10.1371/journal.ppat.1005308. PubMed PMID:26588216 PubMed Central PMC4654494.
  3. Kennedy, S, Beaudoin, T, Yau, YC, Caraher, E, Zlosnik, JE, Speert, DP et al.. Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms. Antimicrob. Agents Chemother. 2015;60 (1):348-55. doi: 10.1128/AAC.02068-15. PubMed PMID:26503664 PubMed Central PMC4704152.
  4. Grasemann, H, Gonska, T, Avolio, J, Klingel, M, Tullis, E, Ratjen, F et al.. Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis. J. Cyst. Fibros. 2015;14 (6):727-32. doi: 10.1016/j.jcf.2015.07.001. PubMed PMID:26168933 .
  5. Wainwright, CE, Elborn, JS, Ramsey, BW, Marigowda, G, Huang, X, Cipolli, M et al.. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N. Engl. J. Med. 2015;373 (3):220-31. doi: 10.1056/NEJMoa1409547. PubMed PMID:25981758 PubMed Central PMC4764353.
  6. Yau, YC, Ratjen, F, Tullis, E, Wilcox, P, Freitag, A, Chilvers, M et al.. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. J. Cyst. Fibros. 2015;14 (2):262-6. doi: 10.1016/j.jcf.2014.09.013. PubMed PMID:25453872 .
  7. Ratjen, A, Yau, Y, Wettlaufer, J, Matukas, L, Zlosnik, JE, Speert, DP et al.. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 2015;59 (1):711-3. doi: 10.1128/AAC.04123-14. PubMed PMID:25348526 PubMed Central PMC4291427.
  8. McKone, EF, Borowitz, D, Drevinek, P, Griese, M, Konstan, MW, Wainwright, C et al.. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med. 2014;2 (11):902-10. doi: 10.1016/S2213-2600(14)70218-8. PubMed PMID:25311995 .
  9. Keenan, K, Avolio, J, Rueckes-Nilges, C, Tullis, E, Gonska, T, Naehrlich, L et al.. Nasal potential difference: Best or average result for CFTR function as diagnostic criteria for cystic fibrosis?. J. Cyst. Fibros. 2015;14 (3):310-6. doi: 10.1016/j.jcf.2014.09.006. PubMed PMID:25300456 .
  10. Konstan, MW, Döring, G, Heltshe, SL, Lands, LC, Hilliard, KA, Koker, P et al.. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J. Cyst. Fibros. 2014;13 (2):148-55. doi: 10.1016/j.jcf.2013.12.009. PubMed PMID:24440167 PubMed Central PMC4755340.
Search PubMed

Affiliations & Other Activities

  • Head, Division of Respirology, St. Michael’s Hospital
  • The Cystic Fibrosis Canada Chair in Adult Cystic Fibrosis Research, St. Michael’s Hospital
  • Professor of Medicine, University of Toronto